CAI

Caris Life Sciences, Inc. is a molecular science company focused on precision medicine and cancer diagnostics. Headquartered in Irving, Texas, Caris provides advanced molecular profiling services that analyze tumors at the DNA, RNA, and protein levels to identify treatment options tailored to individual patients. The company's comprehensive genomic testing platforms evaluate cancer biomarkers and genetic mutations to inform oncologists about targeted therapies, immunotherapies, and clinical trial opportunities. Caris operates CLIA-certified and CAP-accredited laboratories equipped with next-generation sequencing technology and bioinformatics capabilities. The company has profiled hundreds of thousands of tumor samples, building one of the world's largest clinical genomic databases. Caris collaborates with pharmaceutical companies, research institutions, and healthcare providers to advance precision oncology through real-world evidence and biomarker discovery. The company's services span multiple cancer types including lung, breast, colorectal, and rare tumors. Caris employs specialists in molecular biology, pathology, oncology, and data science. The company's business model combines diagnostic testing revenue with data-driven partnerships in drug development and clinical research. Caris aims to improve cancer treatment outcomes by matching patients with therapies most likely to be effective based on their tumor's molecular characteristics.